Crinetics Pharmaceuticals, Inc.
CRNX
$30.93
$0.842.79%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -19.49% | -20.07% | -4.90% | -3.74% | -10.65% |
| Total Depreciation and Amortization | 3.68% | 17.39% | 2.34% | 2.26% | 58.86% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 31.24% | 9.67% | 0.35% | -5.50% | 49.27% |
| Change in Net Operating Assets | 169.23% | -2,996.43% | 85.69% | -122.95% | 248.29% |
| Cash from Operations | 2.94% | -36.77% | -2.95% | -31.86% | 9.86% |
| Capital Expenditure | -158.43% | -20.41% | -94.89% | 44.71% | 28.30% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 148.58% | 84.34% | -2,660.50% | 140.11% | -3,310.60% |
| Cash from Investing | 144.15% | 84.14% | -2,731.11% | 138.41% | -17,459.55% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 59.00% | -99.24% | 896.38% | 1,157.61% | -98.86% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -2,037.10% | -152.86% | 116.45% |
| Cash from Financing | 59.00% | -99.20% | 866.45% | 662.02% | -98.09% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 75.97% | -222.39% | -449.00% | 116.11% | -127.49% |